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Posaconazole Tablet Pharmacokinetics: Lack of Effect of Concomitant
Medications Altering Gastric pH and Gastric Motility in Healthy
Subjects
Walter K. Kraft,a Peter S. Chang,a Marlou L. P. S. van Iersel,b Hetty Waskin,c Gopal Krishna,c* Wendy M. Kersemaekersb
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USAa; MSD, Oss, Netherlandsb; Merck & Co., Inc.,
Whitehouse Station, New Jersey, USAc
Posaconazole oral suspension is an extended-spectrum triazole that should be taken with food to maximize absorption. A new
posaconazole tablet formulation has demonstrated improved bioavailability over the oral suspension in healthy adults in a fast-
ing state. This study evaluated the effects of concomitant medications altering gastric pH (antacid, ranitidine, and esomeprazole)
and gastric motility (metoclopramide) on the pharmacokinetics of posaconazole tablets. This was a prospective open-label 5-way
crossover study in 20 healthy volunteers. In each treatment period, a single 400-mg dose (4 100-mg tablets) of posaconazole was
administered alone or with 20 ml antacid (2 g of aluminum hydroxide and 2 g of magnesium hydroxide), ranitidine (150 mg),
esomeprazole (40 mg), or metoclopramide (15 mg). There was a>10-day washout between treatment periods. Posaconazole ex-
posure, time to maximum concentration of drug in serum (Tmax), and apparent terminal half-life (t1/2) were similar when po-
saconazole was administered alone or with medications affecting gastric pH and gastric motility. Geometric mean ratios (90%
confidence intervals [CIs]) of the area under the concentration-time curve from time zero to infinity (AUC0–inf) (posaconazole
with medications affecting gastric pH and gastric motility versus posaconazole alone) were 1.03 (0.88–1.20) with antacid, 0.97
(0.84–1.12) with ranitidine, 1.01 (0.87–1.17) with esomeprazole, and 0.93 (0.79–1.09) with metoclopramide. Geometric mean
ratios (90% CIs) of the maximum concentration of drug in serum (Cmax) were 1.06 (0.90–1.26) with antacid, 1.04 (0.88–1.23)
with ranitidine, 1.05 (0.89–1.24) with esomeprazole, and 0.86 (0.73–1.02) with metoclopramide. In summary, in healthy volun-
teers, the pharmacokinetics of a single 400-mg dose of posaconazole tablets was not altered to a clinically meaningful extent
when posaconazole was administered alone or with medications affecting gastric pH or gastric motility.
Posaconazole oral suspension (Noxafil; Merck & Co., Inc.,Whitehouse Station, NJ, USA) is a marketed extended-spec-
trum triazole with demonstrated efficacy as prophylaxis and treat-
ment for patients with invasive fungal infection (IFI) (1–5). Po-
saconazole is approved in more than 80 countries worldwide. In
the United States and Europe, posaconazole is approved for the
prophylaxis of IFI in immunocompromised patients and for the
treatment of those with oropharyngeal candidiasis (6, 7). Addi-
tionally, posaconazole is approved in Europe as a treatment for
patients with refractory IFI (7). In a large, multicenter, phase III,
randomized clinical trial in patients undergoing chemotherapy
for acute myelogenous leukemia or myelodysplastic syndrome,
treatment with 200 mg of posaconazole oral suspension 3 times
daily (compared with fluconazole or itraconazole) resulted in
fewer proven or probable IFIs (2% versus 8%; P  0.001), a sta-
tistically significantly lower incidence of invasive aspergillosis (1%
versus 7%), and longer survival (P 0.04) (1). In a large, random-
ized, double-blind, phase III trial in patients with graft-versus-
host disease, 200mg of posaconazole oral suspension 3 times daily
was similar to fluconazole for prophylaxis against IFI and was
superior in preventing invasive aspergillosis (2.3% versus 7%; P
0.006) and reducing the rate of death related to fungal infections
(1% versus 4%; P 0.01) (4). In an externally controlled study in
patients with invasive aspergillosis refractory to or intolerant of
amphotericin B and/or itraconazole, 200 mg of posaconazole oral
suspension 4 times daily demonstrated activity for the treatment
of invasive aspergillosis with an overall success rate of 42% for
posaconazole recipients compared with a rate of 26% for control
subjects (P 0.006) (5).
The pharmacokinetics (PK) of posaconazole oral suspension
has been extensively studied in both healthy volunteers and pa-
tients at risk for IFI (8–15). The bioavailability of posaconazole
oral suspension is significantly enhanced when coadministered
with food, particularly a high-fat meal (12, 16). However, those at
high risk for IFI, such as neutropenic patients undergoing chemo-
therapy for acute myelogenous leukemia or myelodysplastic syn-
drome and recipients of allogeneic hematopoietic stem cell trans-
plants, may be unable to eat because of mucositis, nausea, or
neutropenic enterocolitis (14, 17, 18). The posaconazole label rec-
ommends that posaconazole oral suspension be administered
with food or a nutritional supplement to ensure that adequate
plasma concentrations are attained (6, 7). In patients unable to
eat, the absorption of posaconazole oral suspension may be en-
hanced by dividing the posaconazole doses (200mg 4 times daily)
or by administering the drug with a liquid nutritional supplement
or acidic beverage such as ginger ale (10, 12).
The PK of posaconazole oral suspension has been studied in
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combination with esomeprazole, which increases gastric pH, and
metoclopramide, which increases gastric motility (12). The ad-
ministration of 400mgof posaconazole oral suspension to healthy
volunteers under conditions of increased gastric pH (coadminis-
tered esomeprazole) decreased posaconazole exposures (mean
area under the concentration-time curve [AUC]) by 32% and
21% under fasting conditions and in the presence of an acidic
carbonated beverage, respectively. Furthermore, administration
of 400 mg of posaconazole oral suspension under conditions of
increased gastric motility (coadministered metoclopramide) de-
creased posaconazole exposure (mean AUC) by 19% (geometric
mean ratio [GMR], 0.81, 90% confidence interval [CI] 0.72 to
0.91) in the presence of a nutritional supplement (12).
A new oral tablet formulation of posaconazole has been devel-
oped. The posaconazole tablet formulation consists of active drug
mixed with a pH-sensitive polymer (hypromellose acetate succi-
nate [HPMCAS]), which limits POS release from the tablet when
exposed to a low gastric pH and releases POS at the elevated pH of
the intestine. Furthermore, it is believed that the presence of the
polymer in the intestinal fluid inhibits the recrystallization of POS,
thus ensuring that a greater fraction of the dose is available for
absorption. This results in substantially improved exposure (3-
fold) compared with that for the oral suspension in healthy adults
in the fasting state (19). This attribute of posaconazole tabletsmay
be beneficial in patients with poor food intake or a limited ability
to take the medication with a high-fat meal.
Because the tablet design exploits the pH environment of the
small intestine tomaximize absorption, we wanted to evaluate the
PK and safety of posaconazole tablets in the presence of agents that
alter gastric pH and gastric motility. In the present study, we in-
vestigated the effects of antacid, ranitidine, esomeprazole, and
metoclopramide on posaconazole tablet PK and safety. Antacid,
ranitidine (an H2 receptor functional antagonist), and esomepra-
zole (a proton pump inhibitor) were chosen because they increase
gastric pH in different ways. Metoclopramide, which stimulates
gastric motility, was chosen because it is commonly prescribed to
treat chemotherapy-induced nausea.
(This workwas presented in part at the 52nd Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, San Fran-
cisco, CA, 9 to 12 September 2012.)
MATERIALS AND METHODS
Subjects. This was a randomized prospective open-label 5-way crossover
study in healthy volunteers. It was conducted in accordancewith the prin-
ciples of good clinical practice, and written informed consent was ob-
tained from each subject before any study-related procedures were per-
formed. The protocol was reviewed and approved by an independent
ethics committee (Thomas Jefferson University, PA).
Inclusion and exclusion criteria.Healthymale and female subjects of
any race, who were 18 to 55 years of age (inclusive) and had a body mass
index between 18 and 32 kg/m2 (inclusive), were eligible to be enrolled.
Electrocardiography (ECG) results had to be within normal limits. Clin-
ical laboratory test (complete blood cell count, blood chemistry, and uri-
nalysis) results and vital signs also had to be within normal limits or
clinically acceptable. All subjects had to have negative findings on screen-
ing for drugs with a high potential for abuse. Subjects were excluded if
they had any surgical or medical condition that might significantly alter
the absorption, distribution, metabolism, or excretion of any drug. Sub-
jects were not permitted to take any concomitant medications (except
acetaminophen) within 2 weeks or any investigational drugs within 30
days of the start of the study. Subjects who smoked10 cigarettes per day
(or used an equivalent amount of any tobacco product) were excluded.
Subjects who tested positive for the human immunodeficiency virus, hep-
atitis B virus surface antigen, or hepatitis C virus were also excluded.
Treatment. Subjects received all 5 treatments in a randomized, cross-
over manner with a10-day washout period between each posaconazole
dose. The study drugs were administered in the fasting state (10 h after
an overnight fast), with the first meal approximately 4 h postdose on day
1. In each period, subjects received one of the following:
• A single 400-mg dose (4 100-mg tablets) of posaconazole tablets
administered alone on day 1.
• Posaconazole (400 mg) plus 20 ml of antacid (Mylanta ultimate
strength liquid [2 g of aluminum hydroxide/2 g of magnesium
hydroxide];McNeil Consumer Pharmaceuticals, FortWashington,
PA) on day 1; posaconazole tablets were administered immediately
after antacid.
• Posaconazole (400 mg) plus ranitidine (150 mg twice daily) on day
1; posaconazole tablets were administered 1 h after the first dose of
ranitidine.
• Posaconazole (400 mg) on day 1 plus esomeprazole (40 mg once in
the morning for 5 days [days4 to 1]); posaconazole tablets were
administered at the same time as esomeprazole.
• Posaconazole (400 mg) on day 1 plus metoclopramide (15 mg 4
times daily for 2 days [days1 and 1]); posaconazole tablets were
administered at the same time as metoclopramide.
Pharmacokinetic analysis. Blood samples (4ml) for PK evaluation of
posaconazole in plasma were collected in each treatment period predose
(0 h) and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 120, and 168 h postdose. The
samples were drawn into prechilled K2 EDTA-containing tubes and were
centrifuged within 30 min of collection at 1,500  g for 15 min in a
refrigerated centrifuge (4°C). The plasma was stored at20°C until ana-
lyzed. The samples were transferred to the analytical site on dry ice. The
plasma samples were assayed for posaconazole using a previously de-
scribed validated liquid chromatographywith tandemmass spectrometric
detection method (20) with a lower limit of quantitation of 5 ng/ml and a
calibration range of 5 to 5,000 ng/ml.
Plasma concentrations of posaconazolemeasured after each dosewere
summarized using the following PK parameters: AUC from time zero to
time of the last quantifiable sample (AUC0–last), AUC from time zero to
infinity (AUC0–inf), maximum concentration of drug in serum (Cmax),
time to Cmax (Tmax), and apparent terminal half-life (t1/2).
Statistical analysis. Descriptive statistics were summarized for the
plasma concentrations of posaconazole and the derived PK parameters by
treatment. The AUC0–last and Cmax were analyzed using a linear mixed-
TABLE 1 Subject demographics
Characteristic
Data for all subjects
(n 21)
Age (median [range]) (yr) 38 (24–53)
Sex (no. [%])
Male 18 (86)
Female 3 (14)
Race (no. [%])
White 7 (33)
Black/African American 13 (62)
Asian 1 (5)
Ethnicity, not Hispanic/Latino (no. [%]) 21 (100)
Weight (median [range]) (kg) 78.2 (52.5–105.1)
Height (median [range]) (cm) 175 (158–186.5)
Body mass index (median [range]) (kg/m2) 25.9 (21.0–31.7)
Gastric Agents and Posaconazole Tablet PK
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effects model, extracting the effects due to treatment, period, and se-
quence as fixed effects and effects due to subjects as random effect; a log
transformation was applied and back transformed. Geometric mean ra-
tios (GMRs) of AUC0–last, AUC0–inf, and Cmax (posaconazole plus each
concomitant treatment versus posaconazole alone) and 90% confidence
intervals (CIs) were provided from the linear mixed-effects model. If the
90% CI fell within the range of 0.5 to 2.0, it was assumed there was no
clinically meaningful effect of gastric pH or gastric motility on posacona-
zole PK.
Safety analysis. Safety assessments included reporting of adverse
events (AEs), vital signs, physical examination, ECG, hematology, and
blood chemistry through day 8 of the last treatment period. The AEs were
tabulated by body system or organ class and severity and were summa-
rized by treatment.
RESULTS
Subject demographics. Twenty-one subjects were enrolled in the
study (Table 1). Eighty-six percent of them were male, and 62%
were black or African American; the mean age was 38 years.
Twenty subjects completed the study; 1 subject withdrew consent
and discontinued after the first treatment period. The subject
withdrew consent on day 1 of period 1 and received only a single
dose of antacid and a single oral dose of 400 mg of posaconazole.
Pharmacokinetics. Posaconazole AUC0–last, AUC0–inf, Cmax,
Tmax, and t1/2 values were similar whether posaconazole was admin-
istered alone or with medications affecting gastric pH and gastric
motility (Table 2). The mean (percent coefficient of variation
[%CV]) Cmax values for posaconazole were 1,090 ng/ml (43) when
administered alone compared with 1,112 ng/ml (36), 1,094 ng/ml
(37), 1,104 ng/ml (35), and 935 ng/ml (44) when administered with
antacid, ranitidine, esomeprazole, andmetoclopramide, respectively.
Similarly, mean (%CV) AUC0–inf values for posaconazole were
42,406h ·ng/ml (49)whenadministeredalonecomparedwith42,468
h ·ng/ml (39), 39,287h ·ng/ml (37), 41,574h ·ng/ml (43), and38,513
h ·ng/ml (43)whenadministeredwithantacid, ranitidine, esomepra-
zole, and metoclopramide, respectively. Results were similar for
AUC0–last (Table 2). Median Tmax and t1/2 also appeared to be unaf-
fected by concomitant medication; Tmax ranged from 4 to 4.8 h, and
t1/2 ranged from 27 to 29 h.
Themean plasma concentration-time profiles of posaconazole
tablets administered alone and with antacid, ranitidine, esome-
prazole, and metoclopramide were similar (Fig. 1). AUC0–last,
AUC0–inf, andCmax GMRs (90%CIs) of posaconazole tablets plus
treatment versus posaconazole tablets alone are summarized in
Table 3, and AUC0–last and Cmax GMRs (90% CIs) are presented
graphically in Fig. 2. AUC0–inf GMRs of posaconazole plus treat-
ment compared with that for posaconazole alone were 1.03 for
antacid, 0.97 for ranitidine, 1.01 for esomeprazole, and 0.93 for
metoclopramide. Similarly, Cmax GMRs of posaconazole plus
treatment compared with that for posaconazole alone were 1.06
for antacid, 1.04 for ranitidine, 1.05 for esomeprazole, and 0.86 for
metoclopramide. The 90% CIs of AUC0–last, AUC0–inf, and Cmax
for each comparison to posaconazole alone were fully contained
within the prespecified bounds of 0.5 to 2.0; there was, therefore,
no clinically meaningful effect of gastric pH or gastric motility on
the PK of posaconazole tablets.
TABLE 2 Arithmetic means (%CV) of the pharmacokinetic parameters
of posaconazole after single-dose administration of posaconazole tablets
(400 mg) alone or with concomitant medications to healthy volunteers
Treatment
Pharmacokinetic parameters (arithmetic mean [%CV])a
Cmax
(ng/ml)
AUC0–inf
(h · ng/ml)
AUC0–last
(h · ng/ml) Tmax (h)
b t1/2 (h)
POS alone 1,090 (43) 42,406 (49) 40,967 (47) 4 (2–8) 27.3 (37)
POS antacid 1,112 (36) 42,468 (39) 41,247 (39) 4.8 (3–12) 27.7 (29)
POS ranitidine 1,094 (37) 39,287 (37) 38,046 (35) 4 (3–5) 26.9 (35)
POS esomeprazole 1,104 (35) 41,574 (43) 40,083 (40) 4.5 (3–24) 28.0 (30)
POSmetoclopramide 935 (44) 38,513 (43) 36,975 (40) 4 (2–6) 29.0 (38)
a AUC0–inf, area under the concentration-time curve from time zero to infinity;
AUC0–last, area under the concentration-time curve from time zero to time of the last
quantifiable sample; Cmax, maximum observed concentration of drug in serum; CV,
coefficient of variation; POS, posaconazole; Tmax, time to Cmax; t1/2, apparent terminal
half-life.
b Median (minimum to maximum).
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FIG 1 Arithmetic mean plasma concentration-time profiles after single-dose administration of posaconazole (POS) tablets (400mg) alone or with concomitant
medications to healthy volunteers (inset, semilog scale). n 20 (except for posaconazole antacid, where n 21).
TABLE 3 GMRs (90% CI) of AUC0–inf, AUC0–last, and Cmax for
posaconazole plus treatment compared with those for posaconazole
tablet alonea
Treatment
GMR (90% CI) for POS plus treatment compared with
those of POS tablet alone fora:
Cmax AUC0–inf AUC0–last
POS antacid 1.06 (0.90–1.26) 1.03 (0.88–1.20) 1.04 (0.90–1.20)
POS ranitidine 1.04 (0.88–1.23) 0.97 (0.84–1.12) 0.97 (0.84–1.12)
POS esomeprazole 1.05 (0.89–1.24) 1.01 (0.87–1.17) 1.02 (0.88–1.17)
POSmetoclopramide 0.86 (0.73–1.02) 0.93 (0.79–1.09) 0.93 (0.80–1.07)
a AUC0–inf, area under the concentration-time curve from time zero to infinity;
AUC0–last, area under the concentration-time curve from time zero to time of the last
quantifiable sample; CI, confidence interval; Cmax, maximum observed concentration
of drug in serum; GMR, geometric mean ratio; POS, posaconazole.
Kraft et al.
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Safety. Overall, 19 of 21 (90%) subjects reported at least 1 treat-
ment-emergent AE; all AEs were mild to moderate in severity. No
deaths, seriousAEs, or significantAEswere reported, andno subjects
discontinued treatment because of AEs. The most frequent treat-
ment-emergentAEswere somnolence (8 subjects [38%]),diarrhea (7
subjects [33%]), contusion (6 subjects [29%]), andflatulence (5 sub-
jects [24%]). Fourteen (67%) subjects reported1AE considered to
be treatment related; the most frequent treatment-related AEs were
somnolence (7 subjects [33%]), diarrhea (5 subjects [24%]), andflat-
ulence (3 subjects [14%]).Theremaining treatment-relatedAEswere
reported by only 1 subject each. Dosing was temporarily halted in 2
subjects because of AEs (elevated creatine phosphokinase [CPK] and
oromandibular dystonia); these AEs were transient, and the subjects
remained in the study through completion. The elevated CPK was
not considered treatment related, whereas oromandibular dystonia
was considered to be probably treatment related with the coadmin-
istered drugmetoclopramide. Apart from the elevatedCPK in 1 sub-
ject, no laboratory AEs were reported. No clinically significant
changeswereobserved invital signsorECGfindings inany treatment
group.
DISCUSSION
This randomized, open-label, single-center, 5-way crossover, sin-
gle-dose study evaluated the effects of concomitant medications
that alter gastric pH and gastric motility on the PK of posacona-
zole tablets in healthy volunteers. The PK of a single 400-mg dose
of posaconazole tablets was found to be similar when the drug was
administered alone and when it was administered with antacid,
ranitidine, esomeprazole, or metoclopramide. The AUC0–inf
GMRs of posaconazole plus treatment compared with that of po-
saconazole alone ranged from 0.93 to 1.03, whereas the associated
Cmax GMRs ranged from 0.86 to 1.06. All 90% CIs of AUC0–last,
AUC0–inf, and Cmax for each comparison to posaconazole alone
were fully contained within the prespecified limits of 0.5 to 2.0,
therefore confirming that there was no clinicallymeaningful effect
of gastric pH or gastric motility on the PK of the posaconazole
tablets. Hence, it appears that posaconazole tablets may be coad-
ministered with gastric agents without decreasing posaconazole
exposure. The largest point estimate difference was seen in the
metoclopramide coadministration with 93% systemic exposure
(AUC) compared to that for posaconazole alone. However, the
magnitude of the difference is considered not clinically relevant,
and as the 90% CIs spanned 79% to 109% (AUC0–inf), the differ-
ence was not statistically significant. Although the increased expo-
sure of the tablet formulation compared with that of the oral sus-
pension, especially under fasted conditions, may benefit patients
at risk for low absorption of posaconazole such as those unable to
take the currently marketed oral suspension with food (19), it is
possible that posaconazole tablets may also be beneficial in pa-
tients taking concomitantmedications affecting gastric pH or gas-
tric motility.
In a previous study (12), 400 mg of posaconazole oral suspen-
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FIG 2 Individual ratios, geometric mean ratios (GMRs) (posaconazole [POS] tablets treatment/posaconazole tablets), and 90% confidence intervals (CIs) of
area under the concentration-time curve from time zero to time of the last quantifiable sample (AUC0–last) (A) and maximum concentration of drug in serum
(Cmax) (B) for posaconazole tablets (400 mg) alone or with concomitant treatment.
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sion was administered in healthy volunteers under conditions of
increased gastric pH (coadministered esomeprazole) or increased
gastric motility (coadministered metoclopramide). In contrast to
the present study, posaconazole exposure was decreased with es-
omeprazole administered under fasting conditions and in the
presence of an acidic carbonated beverage and with metoclopra-
mide administered in the presence of a nutritional supplement
(12). The discrepancies in the results between the 2 posaconazole
formulations are consistent with what is understood about how
the formulations are absorbed. The oral suspension is expected to
dissolve in the stomach at low pH; therefore, a lesser amount of
drug is likely to be dissolved if the gastric pH is elevated or if the
gastric residence time is short. In contrast, with the tablet formu-
lation, the drug is primarily released from the polymer in the small
intestine; hence, the drug release is relatively independent of the
gastric pH or residence time.
Posaconazole plasma levels are important for maintaining ef-
ficacy during both prophylaxis and treatment. Although a thresh-
old posaconazole plasma level allowing for breakthrough IFI has
not yet been defined, one study has shown that themedian average
plasma concentration of posaconazole was lower in 5 allogeneic
hematopoietic stem cell transplant recipients with graft-versus-
host diseasewhodeveloped breakthrough IFIswhile on posacona-
zole prophylaxis than in 241 patients who did not develop break-
through IFIs (11). Furthermore, a positive correlation between
exposure and response has been reported in a nonrandomized
trial of posaconazole salvage treatment for invasive aspergillosis
(5). Maintenance of posaconazole plasma concentrations may be
critical in patients at risk for IFI whomust take concomitantmed-
ications that affect gastric pHor gastricmotility. In addition to the
PKfindings in the present study, the 400-mg dose of posaconazole
tablets was well tolerated when administered alone or in combi-
nation with antacid, ranitidine, esomeprazole, or metoclopra-
mide. This finding is of clinical relevance because these drugs may
be prescribed concomitantly with posaconazole.
In conclusion, the PK of a single 400-mg dose of posaconazole
tablets is not altered to a clinically meaningful extent when the
drug is administered alone or with medications affecting gastric
pH or gastric motility in healthy volunteers. These results suggest
that posaconazole tablets may be coadministered with gastric
agents (antacid, ranitidine, esomeprazole, or metoclopramide)
without a clinically important reduction in bioavailability.
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